Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer

Gut

Volumn 62, Issue 8, 2013, Pages 1100-1111

  Wu, Yonghui ^a   Grabsch, Heike ^b   Ivanova, Tatiana ^a   Tan, Iain Beehuat ^a   Murray, Jacinta ^b   Ooi, Chia Huey ^c   Wright, Alexander Ian ^b   West, Nicholas P ^b   Hutchins, Gordon G A ^b   Wu, Jeanie ^a   Lee, Minghui ^a   Lee, Julian ^a   Koo, Jun Hao ^a   Yeoh, Khay Guan ^d   Van Grieken, Nicole ^e   Ylstra, Bauke ^e   Rha, Sun Young ^f   Ajani, Jaffer A ^g   Cheong, Jae Ho ^h   Noh, Sung Hoon ^h   Lim, Kiat Hon ⁱ   Boussioutas, Alex ^j,k   Lee, Ju Seog ^g   Tan, Patrick ^c,l,m   more..

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d Dept Medicine Endocrinol Diabet   (Singapore)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Yonsei University   (South Korea)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h Yonsei University College of Medicine   (South Korea)

ⁱ SINGAPORE GENERAL HOSPITAL   (Singapore)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^m GENOME INSTITUTE OF SINGAPORE   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; GASTRECTOMY; GENDER; GENE EXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; NUCLEOTIDE SEQUENCE; ONSET AGE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STROMA; TRANSCRIPTOMICS;

BARRETT'S CARCINOMA; BARRETT'S METAPLASIA; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CANCER SCREENING; GASTRIC ADENOCARCINOMA; GASTRIC CANCER; GASTRIC PRE-CANCER; GENE EXPRESSION; HELICOBACTER PYLORI-GASTRITIS; HEPATOMA; IMAGE ANALYSIS; LIVER; MOLECULAR PATHOLOGY; OESOPHAGEAL CANCER; PROGNOSTIC FACTORS;

ADENOCARCINOMA; AGE FACTORS; CELL DIFFERENTIATION; DATABASES, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOMICS; HUMANS; NEOPLASM STAGING; PROGNOSIS; SEX FACTORS; STOMACH NEOPLASMS; STROMAL CELLS; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 84880315917     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301373     Document Type: Article

References (69)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Hartgrink HH, Jansen EP, van Grieken NC, et al. Gastric cancer. Lancet 2009;374:477-90.
3. Jackson C, Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):34-6.
4. Ahn JR, Jung M, Kim C, et al. Prognosis of pN3 stage gastric cancer. Cancer Res Treat 2009;41:73-9.
5. Grabsch H, Kerr D, Quirke P. Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours? Histopathology 2004;45:312-34.
6. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010;32:57-65.
7. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241:27-39.
8. Nobili S, Bruno L, Landini I, et al. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol 2011;17:290-9.
9. Scartozzi M, Galizia E, Freddari F, et al. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 2004;30:451-9.
10. Haas M, Dimmler A, Hohenberger W, et al. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 2009;9:65.
11. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000;88:577-83.
12. Caruso RA, Bellocco R, Pagano M, et al. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod Pathol 2002;15:831-7.
13. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 2008;99:1704-11.
14. Alvarado MD, Jensen EH, Yeatman TJ. The potential role of gene expression in the management of primary and metastatic colorectal cancer. Cancer Control 2006;13:27-31.
15. Tsai CJ, Herrera-Goepfert R, Tibshirani RJ, et al. Changes of gene expression in gastric preneoplasia following Helicobacter pylori eradication therapy. Cancer Epidemiol Biomark Prev 2006;15:272-80.
16. Boussioutas A, Li H, Liu J, et al. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res 2003;63:2569-77.
17. Chen X, Leung SY, Yuen ST, et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell 2003;14:3208-15.
18. Hippo Y, Taniguchi H, Tsutsumi S, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002;62:233-40.
19. Tay ST, Leong SH, Yu K, et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res 2003;63:3309-16.
20. Kim SY, Kim JH, Lee HS, et al. Meta- and gene set analysis of stomach cancer gene expression data. Mol Cells 2007;24:200-9.
21. Cho JY, Lim JY, Cheong JH, et al. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 2011;17:1850-7.
22. Aggarwal A, Guo DL, Hoshida Y, et al. Topological and functional discovery in a gene coexpression meta-network of gastric cancer. Cancer Res 2006;66:232-41.
23. Albert R. Scale-free networks in cell biology. J Cell Sci 2005;118:4947-57.
24. Wei H, Persson S, Mehta T, et al. Transcriptional coordination of the metabolic network in Arabidopsis. Plant Physiol 2006;142:762-74.
25. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumours and wounds. PLoS Biol 2004;2:E7.
26. Segal E, Friedman N, Koller D, et al. A module map showing conditional activity of expression modules in cancer. Nat Genet 2004;36:1090-8.
27. IARC. WHO Classification Of Tumours Of The Digestive System. Lyon, France: International Agency for Research on Cancer, 2010.
28. Ooi CH, Ivanova T, Wu J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet 2009;5:e1000676.
29. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001;276:17058-62.
30. Weston GC, Haviv I, Rogers PA. Microarray analysis of VEGF-responsive genes in myometrial endothelial cells. Mol Hum Reprod 2002;8:855-63.
31. Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002;4:859-64.
32. Ten RM, Blank V, Le Bail O, et al. Two factors, IRF1 and KBF1/NF-kappa B, cooperate during induction of MHC class I gene expression by interferon alpha beta or Newcastle disease virus. C R Acad Sci 1993;316:496-501.
33. Sandbo N, Kregel S, Taurin S, et al. Critical role of serum response factor in pulmonary myofibroblast differentiation induced by TGF-beta. Am J Respir Cell Mol Biol 2009;41:332-8.
34. Chai J, Norng M, Tarnawski AS, et al. A critical role of serum response factor in myofibroblast differentiation during experimental oesophageal ulcer healing in rats. Gut 2007;56:621-30.
35. Yang Y, Zhe X, Phan SH, et al. Involvement of serum response factor isoforms in myofibroblast differentiation during bleomycin-induced lung injury. Am J Respir Cell Mol Biol 2003;29:583-90.
36. Cimerman M, Repse S, Jelenc F, et al. Comparison of Lauren's, Ming's and WHO histological classifications of gastric cancer as a prognostic factor for operated patients. Int Surg 1994;79:27-32.
37. Viste A, Eide GE, Halvorsen K, et al. The prognostic value of Lauren's histopathological classification system and ABO blood groups in patients with stomach carcinoma. Eur J Surg Oncol 1986;12:135-41.
38. Chiaravalli AM, Klersy C, Tava F, et al. Lower- and higher-grade subtypes of diffuse gastric cancer. Hum Pathol 2009;40:1591-9.
39. West NP, Dattani M, McShane P, et al. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer 2010;102:1519-23.
40. Weibel ER. Stereological Methods. London, New York: Academic Press, 1979.
41. Australian & New Zealand Journal Of Statistics. Oxford: Blackwell Publishers, 1998.
42. Choi JK, Yu U, Yoo OJ, et al. Differential coexpression analysis using microarray data and its application to human cancer. Bioinformatics 2005;21:4348-55.
43. van Noort V, Snel B, Huynen MA. The yeast coexpression network has a small-world, scale-free architecture and can be explained by a simple model. EMBO Rep 2004;5:280-4.
44. Jordan IK, Marino-Ramirez L, Wolf YI, et al. Conservation and coevolution in the scale-free human gene coexpression network. Mol Biol Evol 2004;21:2058-70.
45. Nayak RR, Kearns M, Spielman RS, et al. Coexpression network based on natural variation in human gene expression reveals gene interactions and functions. Genome Res 2009;19:1953-62.
46. Nakata W, Hayakawa Y, Nakagawa H, et al. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer. Int J Oncol 2011;39:1529-36.
47. Gao CF, Xie Q, Su YL, et al. Proliferation and invasion: plasticity in tumour cells. Proc Natl Acad Sci U S A 2005;102:10528-33.
48. Lee HE, Kim MA, Lee BL, et al. Low Ki-67 proliferation index is an indicator of poor prognosis in gastric cancer. J Surg Oncol 2010;102:201-6.
49. Anatskaya OV, Vinogradov AE. Genome multiplication as adaptation to tissue survival: evidence from gene expression in mammalian heart and liver. Genomics 2007;89:70-80.
50. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-34.
51. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84.
52. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8.
53. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009;326:1216-19.
54. Ng MR, Brugge JS. A stiff blow from the stroma: collagen crosslinking drives tumor progression. Cancer Cell 2009;16:455-7.
55. Courrech Staal EF, Wouters MW, van Sandick JW, et al. The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer 2010;46:720-8.
56. Mesker WE, Junggeburt JM, Szuhai K, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 2007;29:387-98.
57. Josson S, Sharp S, Sung SY, et al. Tumor-stromal interactions influence radiation sensitivity in epithelial- versus mesenchymal-like prostate cancer cells. J Oncol 2010;2010:232831.
58. Muerkoster SS, Werbing V, Koch D, et al. Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma-epigenetic downregulation of caspases. Int J Cancer 2008;123:1751-60.
59. Wu SD, Ma YS, Fang Y, et al. Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev 2012;38: 218-25.
60. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359: 1995-2004.
61. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27.
62. Garber K. Stromal depletion goes on trial in pancreatic cancer. J Natl Cancer Inst 2010;102:448-50.
63. Saadi A, Shannon NB, Lao-Sirieix P, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A 2010;107:2177-82.
64. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
65. Achyut BR, Yang L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011;141: 1167-78.
66. Webber J, Steadman R, Mason MD, et al. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 2010;70:9621-30.
67. Dunkern TR, Feurstein D, Rossi GA, et al. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 2007;572: 12-22.
68. Jain VK, Cunningham D, Chau I. Preoperative and postoperative chemotherapy for gastric cancer. Surg Oncol Clin N Am 2012;21:99-112.
69. Davies K. Malignant hyperthermia may be due to a defect in a large Ca2+ release channel protein. Trends Genet 1990;6:171-2.